Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity

Abstract Programmed death-ligand 1 (PD-L1) and T cell immunoreceptor with Ig and ITIM domains (TIGIT) are two potential targets for cancer immunotherapy, early clinical studies showed the combination therapy of anti-PD-L1 and anti-TIGIT had synergistic efficacy both in the terms of overall response...

Full description

Bibliographic Details
Main Authors: Zhenwei Zhong, Mengyao Zhang, Yanan Ning, Guanchao Mao, Xiaopei Li, Qi Deng, Xiaorui Chen, Dongliang Zuo, Xiangyu Zhao, Ermin Xie, Huajing Wang, Lina Guo, Bohua Li, Kai Xiao, Xiaowen He
Format: Article
Language:English
Published: Nature Portfolio 2022-10-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-22975-7

Internet

https://doi.org/10.1038/s41598-022-22975-7

Similar Items